BIRC5 and ovarian cancer: A dual kinase inhibitor, Lapatinib inhibits survivin in pancreatic, breast and ovarian cancers through the down regulation of ErbB1 and ErbB2 phosphorylation or upregulation in BMI1 expression [133, 155, 156].